Furthermore, the Company affirmed its anticipated 2026 milestones guidance, including commercial guidance around its CNSide Diagnostics business unit.

Plus will host a business update conference call and webcast today at 8:30 a.m. Eastern time to discuss the rebranding, progress to milestones and provide additional detail on the Company’s progress for CNSide® Diagnostics. REYOBIQ™, and its artificial intelligence strategy.

In connection with the rebrand, the Company expects its common stock to begin trading on Nasdaq under the new ticker symbol "CNSY". Shareholders are not required to take any action in connection with the anticipated name and ticker change. The Company expects its new corporate website, cerenome.com, to launch in connection with the ticker change.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.